Neuropace
NPCE
62 hedge funds and large institutions have $234M invested in Neuropace in 2024 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 21 increasing their positions, 10 reducing their positions, and 4 closing their positions.
2,500% more call options, than puts
Call options by funds: $260K | Put options by funds: $10K
350% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 4
126% more capital invested
Capital invested by funds: $103M → $234M (+$130M)
110% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 10
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
29% more funds holding
Funds holding: 48 → 62 (+14)
19.24% more ownership
Funds ownership: 50.67% → 69.91% (+19%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KLP
Kent Lake PR
Anasco,
Puerto Rico
|
+$2.02M |
| 2 |
AC
Armistice Capital
New York
|
+$979K |
| 3 |
Jane Street
New York
|
+$870K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$540K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$496K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$842K |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$398K |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$73.7K |
| 4 |
State Street
Boston,
Massachusetts
|
-$62.5K |
| 5 |
Mitsubishi UFJ Asset Management
Tokyo,
Japan
|
-$61.3K |
NPCE Hedge Fund Activity: Q4 2024 in Review
62 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Neuropace (NPCE) for Q4 2024, worth a combined $234M — up 126% from $103M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new NPCE positions and 4 closed out — a net gain of 14 holders — while 21 added to existing stakes and 10 trimmed.
The largest buyer was Kent Lake PR, adding an estimated $2.02M. The largest seller was Millennium Management, cutting an estimated $842K.
- 62 institutional investors held Neuropace (NPCE) as of Q4 2024, up from 48 in Q3 2024.
- Funds reported $234M of Neuropace stock for Q4 2024, up 126% quarter-over-quarter.
- 18 funds opened new Neuropace positions in Q4 2024 and 4 closed out, a net change of +14 holders.
- The largest Neuropace buyer in Q4 2024 was Kent Lake PR, an estimated $2.02M added.
- The largest Neuropace seller in Q4 2024 was Millennium Management, an estimated $842K sold.
Based on aggregated 13F filings for Q4 2024.